安正时尚集团股份有限公司 内部控制制度 第一章 总则 第一条 为加强安正时尚集团股份有限公司（下称"公司"）内部控制，促进公司规 范运作和健康发展，保护投资者合法权益，根据《中华人民共和国公司法》 （以下简称《公 司法》） 、《中华人民共和国证券法》 （以下简称《证券法》）、 《上海证券交易所股票上市规则》 （以下简称《股票上市规则》） 、《上海证券交易所上市公司自律监管指引第 1 号-规范运作》 等法律法规和规范性文件的规定，结合公司的实际情况，制定本制度。 第二条 公司内部控制制度的目的： （一）保障国家法律、法规、规章及其他相关规定的贯彻落实； （二）保证所有业务活动均按照适当的授权进行，提高公司经营的效益及效率，提升公 司质量，增加对公司股东的回报； （三）保障公司资产的安全、完整并有效发挥作用，防止毁损、浪费、盗窃并降低减值 损失； （四）确保公司信息披露的真实、准确、完整和公平； （五）防止、发现和纠正错误与舞弊，保证账面资产与实物资产核对相符。 第三条 公司董事会对公司内部控制制度的制定和有效执行负责。 第四条 公司内部控制应遵循的原则： （一）全面性原则。内部控制应贯穿决策、执行和监督全过程， ...

恒宝股份有限公司 内部审计制度 （2025 年 8 月修订） 为了规范恒宝股份有限公司 (以下简称"公司")内部审计工作，完善内部 控制制度，确保董事会和股东会等机构合法运作和科学决策，建立有效的激励约 束机制，树立风险防范意识，培育良好的企业精神和内部控制文化，创造全体职 工充分了解并履行职责的环境，特制定本制度。 本制度所称内部控制，涵盖公司经营活动中与财务报告和信息披露事务相关 的所有业务环节，包括：销货与收款、采购及付款、存货管理、固定资产管理、 资金管理、投资与融资管理、人力资源管理、信息系统管理和信息披露事务管理 等。 公司董事会应当对公司内部控制制度的制定和有效执行负责。 公司的人员应当独立于控股股东。公司的高级管理人员在控股股东或 者其控制的企业不得担任除董事、监事（如有）以外的其他行政职务。控股股东 高级管理人员兼任公司董事的，应当保证有足够的时间和精力承担公司的工作。 股股东、实际控制人及其关联人占用或者支配。 《中华人民共和国公司法》 有规范的财务会计制度和对分公司、子公司的财务管理制度。 （以下简称"《公司法》"）、《中华人民共和国证券 息披露等活动的控制，按照深交所有关规定的要求建立 ...

上海众辰电子科技股份有限公司 第一章 总则 第一条 为加强上海众辰电子科技股份有限公司（以下简称"公司"）的内 部控制，促进公司规范运作和健康发展，保护股东合法权益，根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）等法律、行政法规、部门规章和《上海证券交易所股票上 市规则》（以下简称"《上市规则》"）、《上市公司信息披露管理办法》（以 下简称"《管理办法》"）等规定，结合公司实际，特修订完善本制度。 第二条 公司内部控制制度的目的是： （一）确保国家有关法律、法规和公司内部规章制度的贯彻执行； （二）提高公司经营效益及效率，提升公司质量，增加对公司股东的回报； （三）保障公司资产的安全、完整； （四）确保公司信息披露的真实、准确、完整和公平。 第三条 公司董事会对公司内部控制制度的制定和有效执行负责。 第二章 内部控制的内容 第四条 公司的内部控制主要包括：业务控制、会计系统控制、信息传递控 制、内部审计控制等内容。 第五条 公司不断完善其治理结构，确保董事会和股东会等机构的合法运作 和科学决策；公司将逐步建立起有效的激励约束机制，树立风险防范意识 ...

Core Viewpoint - Jiangsu Yawey Machine Tool Co., Ltd. is seeking to issue shares to specific targets, with a total fundraising amount not exceeding 924.5749 million yuan, and the issuance will result in Yangzhou Industrial Development Group becoming the controlling shareholder, with the Yangzhou State-owned Assets Supervision and Administration Commission as the actual controller [3][4][10]. Fundraising and Project Allocation - The proposed fundraising will allocate 303.66 million yuan to the second phase of the servo press and automated stamping line project, while 620.9149 million yuan will be used to supplement working capital and repay bank loans [4][10]. - The first phase of the project began construction in 2023 and is currently in trial production, with a designed capacity of 2,000 presses and 100 automated stamping lines per year [4][10]. Regulatory Approvals and Progress - The fundraising requires approval from the State-owned Assets Supervision and Administration Department, which has not yet been obtained [3][5]. - As of June 20, 2025, the Yangzhou Industrial Development Group's subscription for shares has been approved by the Jiangsu Provincial Government's State-owned Assets Supervision and Administration Commission [6][10]. - The Yangzhou Jiangdu District People's Government has issued a land acquisition announcement for the project site, and the company will participate in the bidding process for the land [8][9]. Financial Sources and Stability - The subscription funds will come from 40% self-owned funds and 60% acquisition loans, with a total fundraising amount of 924.5749 million yuan [11][12]. - The Yangzhou Industrial Development Group has a cash balance of 446 million yuan as of June 30, 2025, which is sufficient to cover the acquisition needs [13]. Shareholding and Control - The Yangzhou State-owned Assets Supervision and Administration Commission does not directly or indirectly hold shares in Yawey Machine Tool, and there are no agreements for voting rights or concerted actions regarding shareholding [14][15]. - The actual controller of the subscription target, Yangzhou Industrial Development Group, has committed not to reduce its holdings in Yawey Machine Tool for six months after the pricing benchmark date [16][17]. Historical Fundraising and Compliance - The company has not changed the use of funds from previous fundraising activities, and all fundraising activities have complied with relevant regulations [18][19][20].

Core Viewpoint - The internal control system of Wuxi Autowei Technology Co., Ltd. aims to enhance risk management, ensure compliance, and protect investors' rights through a structured framework [2][3]. Group 1: General Principles - The internal control system applies to the company and its subsidiaries, focusing on achieving operational efficiency and safeguarding assets [2]. - Internal control is defined as a process implemented by the board, management, and employees to achieve control objectives [2]. - The board is responsible for establishing and implementing effective internal controls, while the management leads daily operations [3]. Group 2: Key Responsibilities - The audit committee supervises the internal control system and ensures compliance by the board and management [3]. - Department heads are accountable for their respective internal control systems and must conduct annual self-assessments [5]. Group 3: Fundamental Requirements - The internal control system must consider the internal environment, risk assessment, control activities, information communication, and monitoring [4]. - The company should establish clear objectives, responsibilities, and authority for each department to ensure effective control [5]. Group 4: Control Activities - The internal control activities encompass all business processes, including R&D, sales, procurement, production, and financial management [6]. - The company emphasizes the management of subsidiaries, ensuring they adhere to the internal control policies [7]. Group 5: Internal Control of Related Transactions - Related transactions must follow principles of honesty, equality, and fairness, with clear approval processes established [8][9]. - The company must maintain an updated list of related parties and ensure compliance with disclosure requirements [9]. Group 6: External Guarantees and Fund Management - The company must adhere to strict approval processes for external guarantees, ensuring risk is managed prudently [10][11]. - Fund usage must comply with established management protocols, ensuring transparency and efficiency [13][14]. Group 7: Monitoring and Evaluation - The internal audit department is responsible for regular checks on the effectiveness of internal controls and reporting findings to the audit committee [19][20]. - The board must review and evaluate the internal control self-assessment report annually, ensuring accountability and improvement [21][22].

Core Points - The internal control system of Yabont Chemical Co., Ltd. aims to strengthen risk management, improve operational efficiency, enhance information reliability, and ensure legal compliance to achieve strategic goals [2][3][4] Group 1: Objectives and Framework - The internal control objectives include risk control, operational efficiency improvement, information reliability enhancement, and legal compliance [2][3] - The internal control framework encompasses environmental control, business control, accounting system control, electronic information system control, information transmission control, and internal audit control [4][5] Group 2: Basic Elements of Internal Control - The basic elements of the internal control system include internal environment, goal setting, factor identification, risk assessment, risk response, control activities, information communication, and supervision [3][4][5] Group 3: Control Activities in Business Cycles - The internal control system covers various business cycles, including sales and collection, procurement and payment, production, fixed assets, monetary funds, related party transactions, financing, investment, research and development, and human resource management [5][6][7] Group 4: Management of Subsidiaries and Related Transactions - The company establishes control policies for managing subsidiaries, ensuring they develop their internal control systems and report significant matters to the parent company [8][9] - Related transactions must adhere to principles of honesty, equality, and fairness, with clear approval processes and disclosure requirements [10][11][12] Group 5: External Guarantees and Fundraising - The internal control for external guarantees emphasizes legality, prudence, mutual benefit, and safety, with strict risk control measures [12][13] - The company must establish a management method for fundraising, ensuring funds are used according to specified purposes and tracked for compliance [14][15] Group 6: Major Investments and Information Control - Major investments require thorough feasibility studies and risk assessments, with ongoing monitoring of project execution and financial performance [16][17] - An information disclosure management system is established to ensure timely and accurate reporting of significant information, with confidentiality measures in place [18][19] Group 7: Internal Audit and Evaluation - An internal audit department is set up to oversee business activities, risk management, and internal controls, reporting directly to the board [20][21] - The company conducts regular evaluations of its internal control effectiveness, addressing any identified deficiencies promptly [22][23]

Core Viewpoint - The document outlines the internal control system of Beijing Beilu Pharmaceutical Co., Ltd., emphasizing the importance of compliance, efficiency, asset security, and accurate information disclosure to protect investors' rights and ensure the company's healthy development [1][2]. Summary by Sections General Principles - The internal control system aims to provide reasonable assurance for compliance with laws, operational efficiency, asset security, and accurate information disclosure [1]. - The company must develop its internal control system based on its operational characteristics and environment, adhering to relevant regulations [1][2]. Basic Requirements for Internal Control - The company is responsible for establishing a robust internal control system to ensure legal operations and scientific decision-making [2]. - Clear definitions of goals, responsibilities, and authority for each department and position are essential [2][3]. - Internal control activities should cover all business segments related to financial reporting and information disclosure [2][3]. Management Control of Subsidiaries - The company must establish control policies for its subsidiaries, ensuring they develop their internal control systems [7]. - Regular analysis of subsidiaries' financial reports and performance is required to maintain oversight [7]. Internal Control of Related Transactions - A robust internal control system for related transactions must be established, ensuring fairness and transparency [8][9]. - Related transactions must be disclosed and approved by independent directors before board review [8][9]. External Guarantee Internal Control - The company must adhere to legal and prudent principles when providing external guarantees, ensuring risk control [10][11]. - Approval processes for external guarantees must be clearly defined in the company's articles of association [10][11]. Use of Raised Funds Internal Control - The management of raised funds should follow principles of regulation, safety, efficiency, and transparency [15][16]. - Strict approval processes for the use of raised funds must be established, ensuring compliance with the investment plan [15][16]. Major Investment Internal Control - Major investments must be approved by the board or shareholders, with a focus on risk control and investment effectiveness [17][18]. - The company should conduct feasibility studies and risk assessments for significant investment projects [17][18]. Information Disclosure Internal Control - An information disclosure management system must be established to ensure timely and accurate reporting of significant information [19][20]. - The board secretary is responsible for managing external communications and ensuring compliance with disclosure obligations [19][20]. Internal Control Evaluation and Reporting - An internal audit department should be established to oversee the implementation of internal control systems and the accuracy of financial information [26][27]. - The audit committee is responsible for guiding and supervising the internal audit department's work [26][27].

Core Viewpoint - Huasheng Technology (SZ000790) has received an administrative regulatory decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, leading to a requirement for corrective measures and warnings issued to key executives [2][4][5]. Group 1: Accounting Issues - The company has been found to have irregular accounting practices, including misclassification of advertising expenses as intangible assets by its subsidiary Hainan Rongsheng Hong Technology Co., Ltd. in 2021 [2]. - In 2023, another subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., recognized revenue from medical device sales without actual transfer of control to customers, leading to subsequent returns [2]. - Additionally, sales expenses from Chengdu Yuanhong Mineral Water Co., Ltd. were incorrectly accounted for in other subsidiaries, affecting performance assessment accuracy [2]. Group 2: Non-operational Fund Occupation - In 2021, Hainan Huasheng Development Holding Co., Ltd., a subsidiary, prepaid non-main business contract funds, which were later returned after five months, during which some funds flowed into companies controlled by the actual controller, constituting non-operational fund occupation [3]. Group 3: Internal Control Deficiencies - The internal control systems of the subsidiaries are inadequate, with issues such as improper expense reimbursement documentation and non-compliance with procurement management protocols [3]. - The company lacks a robust internal control system for large non-main business expenditures, leading to non-operational fund occupation in 2021 [3]. Group 4: Executive Accountability - Key executives, including Huang Mingliang (Chairman and President), Li Jun (Vice President and CFO), and Song Gang (Vice President), have been held responsible for the identified accounting and internal control issues [4][5]. Group 5: Company Performance - In 2024, Huasheng Technology reported revenue of 864 million yuan, a year-on-year decrease of 13.89%, and a net profit attributable to shareholders of -6.69 million yuan, down 124.19% [8]. - In the first quarter of 2025, the company achieved revenue of 127 million yuan, a decline of 29.21%, with a net profit of -14.59 million yuan, a drop of 740.09% year-on-year [9].

《公司章程》和《公司监事会议事规则》的要求。本次会议由监事会主席 朱琬瑜女士主持。 本次会议以投票表决的方式，形成以下决议： 证券代码：002030 证券简称：达安基因 公告编号：2025-006 广州达安基因股份有限公司 第八届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州达安基因股份有限公司（以下简称"公司"、"达安基因"）第八届监事 会第六次会议于 2025 年 3 月 17 日以邮件的形式发出会议通知，并于 2025 年 3 月 27 日（星期四）上午 11∶30 在广州市高新区科学城香山路 19 号公司一楼会 议室现场召开。会议应到 5 名监事，实到 4 名监事，监事胡腾女士因工作原因委 托监事黄立强先生代为出席并行使表决权。会议的召开符合《中华人民共和国公 司法》、 一、会议以 5 票赞成，0 票反对，0 票弃权的表决结果审议通过了公司《2024 年度监事会工作报告》。 公司《2024 年度监事会工作报告》全文详见公司指定信息披露网站（http: //www.cninfo.com.cn）。 本报告尚须提交 2024 ...